Shanghai Allist Pharmaceuticals (688578) Q2 2026 earnings summary

Executive summary

• Achieved revenue of RMB 3.32 billion in H1 2026, up 39.85% year-over-year, driven by strong sales of core oncology products and expanded market coverage.

• Net profit attributable to shareholders reached RMB 1.54 billion, up 46.57% year-over-year, with adjusted net profit up 50.99%.

• Core products, including Furmonertinib, Glecirasib, and Pralsetinib, maintained robust growth, supported by inclusion in the national reimbursement drug list.

• Significant R&D progress with multiple pipeline advancements and new indications approved or in late-stage trials.

Financial highlights

• Operating income: RMB 3,319.8 million, up 39.85% year-over-year.

• Net profit attributable to shareholders: RMB 1,540.8 million, up 46.57% year-over-year.

• Adjusted net profit (excluding non-recurring items): RMB 1,366.7 million, up 50.99% year-over-year.

• Basic and diluted EPS: RMB 3.42, up 46.57% year-over-year.

• Operating cash flow: RMB 1,444.6 million, up 32.21% year-over-year.

• R&D investment: RMB 254.2 million, down 14.30% year-over-year, representing 7.66% of revenue.

• Total assets: RMB 9,441.8 million, up 19.45% from year-end 2025.

Outlook and guidance

• Continued focus on oncology innovation, with multiple late-stage clinical trials and new product launches planned.

• Expansion into new tumor types and international markets, including strategic partnerships for ADCs and global clinical studies.

• Ongoing investment in R&D and talent to sustain pipeline growth and maintain competitive advantage.